Navigation Links
Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
Date:3/25/2008

Furthers firm design and development efforts that focus on usability and

rapid commercialization

SAN FRANCISCO, March 25 /PRNewswire/ -- Hiemstra Product Development, an innovative, product design and development company, serving the life sciences industry, today announced the appointment of Daniel C. Rosenman as Vice President of Research & Development. As the company continues to expand, Dan furthers Hiemstra's commitment to the design and engineering of medical technologies that focus on usability and rapid commercialization.

Dan joins Hiemstra with over 16 years of R&D, operations, clinical, regulatory and quality systems experience in the life sciences industry. He has developed novel medical technologies in diverse clinical areas including general surgery, gynecology, orthopedics, urology, cardiac surgery, interventional cardiology, and ophthalmology, in both large companies and early-stage ventures. He began his life science career as an R&D engineer, specializing in bioabsorbable polymers, with Ethicon, Inc., a Johnson & Johnson company. Dan was one of the early employees at med tech start-ups, Heartport, Inc. and BioCardia, Inc., where he led the R&D efforts from the initial founding, to financing and through commercialization. Dan was the first employee at Transcend Medical, Inc., a venture-backed ophthalmic company. Within months of joining Transcend, he completed research, development and clinical milestones that resulted in series A funding. Dan holds over 27 U.S. patents in the medical field and has other global patents pending. He has co-authored several scientific and clinical publications in collaboration with clinical leaders at Stanford University, Massachusetts General Hospital, and HELIOS Hospital, Siegburg, Germany.

"My passion is to enable clients to develop their novel medical technologies for clinicians and, ultimately, patients," explains Rosenman. "At Hiemstra, our unique product develo
'/>"/>

SOURCE Hiemstra Product Development
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Hiemstra Approved to Manufacture Medical Devices in New CER
2. AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer
3. Digirad Corporation Appoints John W. Sayward to Its Board of Directors
4. NutraCea Appoints New Chief Financial Officer
5. Transplant Network Appoints Cynthia Siljestrom CEO
6. Solera Holdings, Inc. Appoints Jason Brady as General Counsel
7. The Childrens Hospital of Philadelphia Appoints New Chief Nursing Officer
8. InnerPulse, Inc. Appoints Elsa Chi Abruzzo as Vice-President of Regulatory and Quality Affairs
9. Ventas Appoints James D. Shelton and Robert D. Reed to Board
10. Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer
11. China Sky One Medical, Inc. Appoints Four Independent Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Dr. Redlener Applauds Historic Effort but Points out Potential Risk if America,s Safety Net Programs Are Lost in Final Health Care Reform ,, NEW YORK, Dec. 4 The New England Journal of Medicine
(Date:12/4/2009)Whether the H1N1 virus will come back during winter isn,t known, CDC says, , , FRIDAY, Dec. 4 (HealthDay News) -- The number of states reporting widespread swine flu activity continued to decl
Breaking Medicine News(10 mins):Health News:Are angry women more like men? 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Swine Flu Continues to Wane 2
...sparked new fears over the safety of Scottish farm...o more than two portions a year.// Researche...tate University, concluded that the health benefit...e health risks will outweigh the benefits, accordi...
...accident has been described as an environmental tr...he blaze. The flames are reportedly spewing out a ...her explosion from a highly volatile fuel tank led...50 fire service personnel drawn from 16 fire servi...
...y the common cold, according to a Newcastle Univer...caused by relatively minor ailments like a respira...ore in the case of those who are genetically susce...nt of a vaccine which will serve to protect childr...
...Palliative care for treatment of chronic diseases ...itals, which has been reported in the Journal of P...patients where chemotherapy or other treatments no...r palliative care. Palliative care programs prov...
...d a non-invasive sensor that will help treat patie... When a patient faces respiratory distress in ... concentrations of oxygen via a mask. But for some...es precious minutes, but the non-invasive sensor c...
...the death of Rene Anderson who took part in a tria...x drug is derived from the plant, and it has been ...ministered to Rene Anderson for relieving her of p...pneumonia and kidney failure. The manufacturers of...
Other Medicine News:Health News:Salmon's own diet sure to affect yours 2Health News:Firefighters Continue To Battle Blaze 2
(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present
(Date:12/4/2009)SALT LAKE CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy wi
(Date:12/4/2009)ANNAPOLIS, Md., Dec. 4 PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new d
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Regence Launches Effort to Further Health Care Debate 51852 1Regence Launches Effort to Further Health Care Debate 51852 2Regence Launches Effort to Further Health Care Debate 51852 3Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 1Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 2Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 3Industry Veterans Rash and Rutledge Launch RegionalCare Hospital Partners to Acquire and Operate Hospitals in Non Urban Markets 51850 4Cornerstone Therapeutics Submits Regulatory Filing for Extended Release Antitussive Product 51848 1Cornerstone Therapeutics Submits Regulatory Filing for Extended Release Antitussive Product 51848 2Cornerstone Therapeutics Submits Regulatory Filing for Extended Release Antitussive Product 51848 3Cornerstone Therapeutics Submits Regulatory Filing for Extended Release Antitussive Product 51848 4Cornerstone Therapeutics Submits Regulatory Filing for Extended Release Antitussive Product 51848 5
...SEARCH TRIANGLE PARK, N.C., July 27 Timothy Mastr...tional (FHI) on August 1st,as Senior Director of R...rch into pre-exposure prophylaxis (PrEP) for HIV p...Mexico City., Dr. Mastro,s presentation, titled "...ls," will examine ongoing and upcoming clinical tr...
...nancing will advance the company,s clinical develo... technology platform, PRINCETON, N.J., July 28 C...tical company developing novel,products based on p...y,announced that it raised in excess of $22.5 mill...Series B investors participated in the financing a...
Other Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 3
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: